Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)

Data ReadoutpositiveZenocutuzumabPositive

AI Analysis

Summary

Partner Therapeutics announced publication of positive eNRGy trial results for Zenocutuzumab in NRG1+ cholangiocarcinoma patients in the Journal of Clinical Oncology, demonstrating meaningful antitumor activity with substantially reduced toxicity compared to existing standards of care.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Zenocutuzumab demonstrated meaningful and durable antitumor activity with substantially reduced toxicity and no treatment-limiting safety concerns

Importance:7/10

Sentiment:

0.80

publicationclinical trial resultsJournal of Clinical OncologycholangiocarcinomaNRG1+safety profile

Related Companies

$DFPH

Read the original article

Published by PR Newswire Biotech on July 2, 2026 10:30 AM

Read Original